2C9N image
Deposition Date 2005-12-13
Release Date 2006-02-21
Last Version Date 2023-12-13
Entry Detail
PDB ID:
2C9N
Keywords:
Title:
Structure of the Epstein-Barr virus ZEBRA protein at approximately 3. 5 Angstrom resolution
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
3.30 Å
R-Value Free:
0.36
R-Value Work:
0.36
R-Value Observed:
0.36
Space Group:
C 1 2 1
Macromolecular Entities
Polymer Type:polydeoxyribonucleotide
Molecule:5'-D(*CP*AP*CP*TP*GP*AP*CP*TP*CP*AP *T)-3'
Chain IDs:A
Chain Length:11
Number of Molecules:1
Biological Source:HUMAN HERPESVIRUS 4
Polymer Type:polydeoxyribonucleotide
Molecule:5'-D(*CP*AP*TP*GP*AP*GP*TP*CP*AP*GP *T)-3'
Chain IDs:B
Chain Length:11
Number of Molecules:1
Biological Source:HUMAN HERPESVIRUS 4
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:BZLF1 TRANS-ACTIVATOR PROTEIN
Gene (Uniprot):BZLF1
Chain IDs:C (auth: Y), D (auth: Z)
Chain Length:63
Number of Molecules:2
Biological Source:HUMAN HERPESVIRUS 4
Ligand Molecules
Primary Citation
Structural Basis of Lytic Cycle Activation by the Epstein-Barr Virus Zebra Protein
Mol.Cell 21 565 ? (2006)
PMID: 16483937 DOI: 10.1016/J.MOLCEL.2006.01.006

Abstact

Epstein-Barr virus (EBV) causes infectious mononucleosis and is linked to several human malignancies. EBV has a biphasic infection cycle consisting of a latent and a lytic, replicative phase. The switch from latent to lytic infection is triggered by the EBV immediate-early transcription factor ZEBRA (BZLF1, Zta, Z, EB1). We present the crystal structure of ZEBRA's DNA binding domain bound to an EBV lytic gene promoter element. ZEBRA exhibits a variant of the basic-region leucine zipper (bZIP) fold in which a C-terminal moiety stabilizes the coiled coil involved in dimer formation. The structure provides insights into ZEBRA's broad target site specificity, preferential activation of specific EBV promoters in their methylated state, ability to dimerize despite lacking a leucine zipper motif, and failure to heterodimerize with cellular bZIP proteins. The structure will allow for the design of new therapeutic agents that block activation of the EBV lytic cycle.

Legend

Protein

Chemical

Disease

Primary Citation of related structures